Evidence map›Paper›PMID 42831101›Full record

ArticleMolecular therapy. Nucleic acids2026

Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles.

Apoorva Ramamurthy, Giulia Scimonelli, William L Murphy, Krishanu Saha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Apoorva RamamurthyWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA.
Giulia ScimonelliWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA.
William L MurphyDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI, USA.
Krishanu SahaWisconsin Institute for Discovery, University of Wisconsin-Madison, Madison, WI, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Assembly of Novel Gene Editing Particles to Understand Genome Surgery in Patient-Derived CellsR35GM119644 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI SAHA, KRISHANU · 2016 to 2025
$4.0M
Label-free imaging of CAR T cell metabolismR01CA278051 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Christian Capitini, Krishanu Saha · 2023 to 2026
$2.6M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA278051NIGMS NIH HHS R35 GM119644
6 · The paper itself

Abstract

Human T cells modified with nucleic acids constitute a powerful and emerging therapeutic modality for cancer, autoimmune disorders, and aging-related diseases. However, delivering nucleic acids, such as mRNA encoding synthetic receptors, transcription factors, cytokines, or genome editors to T cells can be challenging, as nucleic acids can unintentionally reduce viable T cell yield and function, particularly when delivered sequentially

Indexed as

CAR T cell engineeringcell therapy manufacturingDOPEDOTAPelectroporationLNPmRNA deliveryMT: Delivery Strategiesnon viral gene deliveryT cells

Identifiers

PMID42831101
PMCPMC13634528

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.